Excited to kick off the ML for Drug Discovery Summer School Portal with opening remarks from Prudencio M Tossou and the first lecture with Bharath Ramsundar on principles and applications of ML for drug discovery. Looking forward to the next few days of classes!

Today we opened our office in #London – the epicenter for #TechBio in Europe & home to one of the world’s best talent pools across #tech, #biology and #chemistry. Chris Gibson Howard Dawber Michael Bronstein Nathan Benaich Zavain Dar Valence Labs Kristina Ulicna 👩‍💻 Dan

In a new paper, researchers from Recursion & Valence Labs reveal the next level of scaling #microscopy images for use in biological research – offering a significant improvement over weakly supervised learning (WSL). They are presenting their findings at CVPR June 18-19. 🧵

Thanks to everyone who came out and hope to see you again next year!

Excited to be hosting the #Moml2024 where more than 250 people are gathered around 40+ posters Mila - Institut québécois d'IA Jonny

What better way to close the conference than a presentation of AlphaFold3, probably one of the first public presentations about it. From Max Jaderberg , Isomorphic Labs You can join Portal to find out about our next events and newsletter

Our London office is now officially open

Today's benchmarking landscape for ML in drug discovery is complicated. We want to help the community develop methods that matter!🌟 Join us for our launch party at ICML on July 25th to learn more: lu.ma/wj1agv8o

Last year at #ICML, we launched Valence Labs – an #ML research lab in #Montreal to develop next gen cutting-edge methods & models for drug discovery, w/ a focus on #openscience & academic partnerships. This year, we’re helping to launch Polaris - benchmarks for ML in drug

1/ 🚀Today, we’re excited to launch Polaris! 🚀 Polaris is a platform where the ML community working on drug discovery problems can easily share and access datasets and benchmarks. Get started with just a few lines of code: polarishub.io

Huge milestone in our partnership with Roche and Genentech, with many more to come!

Did you see the big news? Want to know more? Join us for our L(earnings) Call today, 8:30am ET/6:30am MT on Thursday, August 8, where we provide a real-time livestream of the Company’s latest business developments from Co-founder and CEO Chris Gibson , Chief R&D and Chief

[1 of 7] Data is the differentiator. Today, we’re kicking off a series called Data Deep Dive – sharing how we collect, model & analyze #data in order to solve challenging biological problems and transform drug discovery. 🧵#datadeepdive

Introducing a small portion of proprietary phenomics data from Recursion into the training of MolGPS, our foundation model for molecular property prediction, led to massive performance increases on new & existing benchmarks. Learn more about the impact of data & scale.

Recursion is a company to watch. Arguably the strongest upstart in deep learning aided drug discovery.

We’ve released an improved version of SynFlowNet! SynFlowNet can now handle large action spaces (up to 220k building blocks) and we experiment with training different GFlowNet backward policies. (1/3) arXiv: arxiv.org/abs/2405.01155 code: github.com/mirunacrt/synf…

Love the momentum behind Polaris right now and super excited to see Leash Bio's massive BELKA dataset up on the platform.

🛡️ New Certified Dataset and Benchmark! Did you know that high-dimensional data like cell images (i.e. phenomics) can help us understand the relationship between compounds and genes? Now you’ll have a chance to work with a phenomics dataset and benchmark to predict which genes

Yay! Polaris is now hosting the RxRx3-core phenomics dataset and introduced a new standard for benchmarking compound-gene activity!

1/ Valence Labs is bringing together next generation of Montréal researchers and innovators in Bio-AI. We are hosting a Bio-AI Show & Tell — a quick and fun showcase of ideas, demos and projects in ML. RSVP here: luma.com/n47bshdx